A recent report from England, about the first-generation oral bisphosphonate sodium clodronate, claims to improve overall survival in men with metastatic but not localized prostate cancer, according to long-term data from two randomized controlled trials. Among the sample of 278 men all who had metastatic disease starting and who were responding to long-term hormone therapy, [...]
I remember when I was approximately Dev's age and computers were huge, often not in color and required floppy disks that were actually floppy. I can see clearly in my mind the old-school CRT monitors and the lousy pixilation with the constantly blinking DOS cursor. Clunky keyboards were common and I'm pretty sure there was [...]
Presented at EAU on March 23, 2009 The drug Denosumab has shown itself both easy to tolerate by patients as well highly able to increases bone mineral density (BMD) when compared with placebo in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT). The results of this multi-centre, randomized, double-blind, placebo-controlled, phase 3 study [...]
One of the unsettled debates in our advanced prostate cancer world surrounds the issue of continuous vs. intermittent hormone therapy (IHT). Traditionally, hormone therapy was continuous, or once you started you never stopped the treatment. As many of us know, hormone therapy is notorious for damaging the quality of life. Hot flashes, loss of libido, [...]
That is the big question I am dealing with this week. I have been so pleased with my recent success with lowering my PSA, but the last test has reversed the trend. My PSA has shown a drastic rise. It went from just under .60 to almost 2.0 within a two week period! As we [...]